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Abstract
Background: Given the increasing worldwide incidence of diabetes, methods to assess diabetes risk which would identify
those at highest risk are needed. We compared two risk-stratification approaches for incident type 2 diabetes mellitus
(T2DM); factors of metabolic syndrome (MetS) and a previously developed diabetes risk score, PreDxH Diabetes Risk Score
(DRS). DRS assesses 5 yr risk of incident T2DM based on the measurement of 7 biomarkers in fasting blood.
Methodology/Principal Findings: DRS was evaluated in baseline serum samples from 4,128 non-diabetic subjects in
the Inter99 cohort (Danes aged 30–60) for whom diabetes outcomes at 5 years were known. Subjects were classified
as having MetS based on the presence of at least 3 MetS risk factors in baseline clinical data. The sensitivity and false
positive rate for predicting diabetes using MetS was compared to DRS. When the sensitivity was fixed to match
MetS, DRS had a significantly lower false positive rate. Similarly, when the false positive rate was fixed to match
MetS, DRS had a significantly higher specificity. In further analyses, subjects were classified by presence of 0–2, 3 or
4–5 risk factors with matching proportions of subjects distributed among three DRS groups. Comparison between
the two risk stratification schemes, MetS risk factors and DRS, were evaluated using Net Reclassification
Improvement (NRI). Comparing risk stratification by DRS to MetS factors in the total population, the NRI was 0.146
(p=0.008) demonstrating DRS provides significantly improved stratification. Additionally, the relative risk of T2DM
differed by 15 fold between the low and high DRS risk groups, but only 8-fold between the low and high risk MetS
groups.
Conclusions/Significance: DRS provides a more accurate assessment of risk for diabetes than MetS. This improved
performance may allow clinicians to focus preventive strategies on those most in need of urgent intervention.
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Introduction
The health and economic burden of diabetes mellitus, primarily
type 2 diabetes (T2DM), is large today and expected to increase
significantly in the next 15–25 years. By 2030, 4.4% (about 370
million people) of the global population is expected to have
diabetes [1], a disease that is expected to rank seventh in the world
as the leading cause of deaths and eleventh as the leading cause of
disability adjusted life years lost [2]. In the United States in 2007,
approximately 7.8% of adults (i.e. about 24 million people) had
diabetes, primarily type 2, while nearly 23% of people in the age
group 60 years or older were diabetic [3].
Due to the morbidity, mortality and cost associated with T2DM,
it will be beneficial to identify individuals who are at higher risk for
developing the disease and who specifically may benefit from
intensive diabetes prevention strategies [4,5]. Impaired fasting
glucose (IFG) (i.e. fasting plasma glucose between 5.6 and
6.9 mmol/L; 100–125 mg/dL) is considered to be a prediabetic
state. Indeed, 9–37% of patients with IFG develop T2DM in a
period of 2.5–11.5 years [6,7,8,9,10]. Yet, this measure of glucose
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in a large number of individuals with IFG.
The presence of metabolic syndrome has also been used to
identify subjects at higher risk for the development of T2DM.
Metabolic syndrome (MetS) is a cluster of risk factors that are
associated with increased risk for diabetes and/or cardiovascular
disease [11,12,13,14]. In accordance with a recent consensus
definition of MetS, these risk factors include central obesity/large
waist circumference, elevated blood pressure, elevated fasting
serum triglycerides, reduced fasting HDL and elevated fasting
plasma glucose [12]. An individual is considered to have MetS if
three of the five criteria are present [12]. It is difficult to estimate
the number of people with MetS as the definitions used in various
parts of the world and by various medical or health organizations
differ [11]. The strong association between factors of the
metabolic syndrome and incident diabetes was reviewed recently
[15,16]. Depending on the criteria used to define metabolic
syndrome, the average relative risk ranged from 3.5–5.2 [15].
This association was stronger for diabetes than for coronary heart
disease [16].
Recently, Nichols and Moler assessed the risk of developing
T2DM in a cohort of 58,056 North American subjects $30 years
old based on whether or not levels of the five MetS components
were abnormal at baseline [17]. Risk of T2DM increased with the
number of abnormal MetS components present. However, the
incidence of T2DM associated with three or more MetS factors
ranged between 1.8% and 28.2% depending on which specific
combination of factors was present. This variability of risk
associated with solely counting the number of abnormal MetS
components may limit their use for assessment of risk for T2DM in
clinical practice.
Another approach for assessing risk of T2DM utilizes risk scores
or models [18,19,20,21,22,23,24,25,26,27,28] which incorporate
variables such as clinical metrics, biomarker levels and family
history of diabetes. The PreDxH Diabetes Risk Score (DRS)
utilizes quantitative measures of seven blood-borne biomarkers
(adiponectin, C-reactive protein, ferritin, glucose, hemoglobin
A1C (HbA1c), interleukin 2 receptor a (IL2Ra) and insulin) in a
multi-marker algorithm. DRS is a score from 1–10 which
corresponds to the risk of developing T2DM within five years
[21,25]. The area under the receiver operating characteristic curve
(AUC) of the DRS was 0.837 in a validation cohort obtained from
a Danish population; this performance was significantly better
compared to more common risk assessment tools such as HbA1c,
fasting insulin, homeostasis model assessment of insulin resistance
(HOMA-IR), fasting glucose or a noninvasive clinical model [25].
In this study the risk of developing T2DM was assessed using
DRS or MetS in the Inter99 cohort, a group of adult Danish
subjects who were followed for at least five years [29]. More
specifically, the objective of this study was to compare the accuracy
of each of these approaches, based on their use in current clinical
practice, for identifying the subjects in this cohort who developed
T2DM during the study using information obtained at baseline.
The accuracy of these two prediction metrics for incident T2DM
was assessed in an unselected population as well as a sub-
population of the cohort which was considered to be at increased
risk for diabetes based on the presence of IFG and/or elevated
HbA1c (eHbA1c) [30].
Materials and Methods
Ethics Statement
The Inter99 study was approved by Copenhagen County
Scientific Ethical Committee (reference number KA 98 155;
ClinicalTrials.gov ID-no: NCT00289237) [29] and all participants
gave written consent to participation in the study.
Subjects
Subjects for this study were from the Inter99 cohort, a random
population of subjects from the southwestern part of Copenhagen
County, Denmark enrolled in a prevention study for cardiovas-
cular disease. Although this was a lifestyle intervention trial for
cardiovascular disease, the 5-year rate of progression to type 2
diabetes observed in this study (4.1%) was similar to other
estimates of progression for this age group [31]. Of the 6,784
subjects who participated at baseline assessment, serum samples
were available from 5,764 subjects. Subjects were excluded from
the present study if they had T2DM at baseline, necessary
measures needed for the analyses were not available, or assessment
of diabetes outcomes was not available at five year follow-up.
Diagnosis of T2DM was based upon criteria from the World
Health Organization defined as either a 2-h plasma glucose of
$11.1 mmol/L ($200 mg/dL) from an oral glucose tolerance test
(OGTT) or fasting plasma glucose (FPG) of $7.0 mmol/L
($126 mg/dL) [32]. There were 4,128 subjects included in this
study after applying the exclusion criteria. At each visit, data were
collected regarding lifestyle, anthropometric measures (e.g. blood
pressure, waist circumference, height, weight), routine laboratory
measures (e.g. HbA1c, FPG and lipids), and OGTT as described
previously [29].
Determination of Diabetes Risk Score
The risk of developing T2DM within five years of baseline was
expressed as DRS, which was calculated from quantitative
measures of seven circulating biomarkers in baseline blood
samples [21,25]. Quantification of FPG, fasting serum insulin
and HbA1c was determined at Steno Diabetes Center, Copenha-
gen, Denmark [29]. HbA1c concentrations were determined by
ion exchange HPLC (Bio-Rad, USA) with a coefficient of variation
of 11%. Quantification of fasting serum adiponectin, C-reactive
protein, ferritin and IL2Ra was done at the Tethys Clinical
Laboratory, Emeryville, CA. Ferritin was measured using solid-
phase, two-site chemiluminescent immunometric assays. C-
reactive protein (CRP) was measured using an immuno-turbido-
metric assay and adiponectin and IL2Ra were measured using a
sandwich immunoassay format. In the validation of these assays,
the coefficients of variation for ferritin, IL2Ra, CRP and
adiponectin were 4.6%, 6.8%, 12.5% and 6.2%, respectively.
DRS was previously trained on a nested case-control subset of 799
subjects from the Inter99 population [25]. For the current analysis,
DRS was calculated from all available subjects (n=4,128),
including those from the case-control training study. Subjects
with missing data for one or more DRS variables were excluded
from the current analysis. All biomarker measurements in this
study were obtained from previously unused aliquots and were run
in a randomized order.
Components of Metabolic Syndrome
Abnormal levels of components which are associated with
the metabolic syndrome were: 1) elevated fasting glucose
($5.6 mmol/L; 100 mg/dL); 2) elevated blood pressure (systolic
$130 mmHg or diastolic $85 mmHg) or on anti-hypertensive
drug treatment; 3) reduced fasting serum HDL cholesterol
(,1.0 mmol/L/40 mg/dL in men or ,1.3 mmol/L/50 mg/
dL/ in women) or on lipid lowering drug treatment; 4) elevated
fasting serum triglycerides ($1.7 mmol/L/150 mg/dL) or on
drug treatment; and 5) elevated waist circumference ($80 cm in
women; $94 cm in men) [12].
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To evaluate the performance of DRS in assessing risk of
developing diabetes, sensitivity and specificity of the DRS was
compared to metabolic syndrome. Because the DRS is a
continuous score, a DRS cut-point was selected to match the
sensitivity of metabolic syndrome, a dichotomized variable, and
specificity was then compared. Similarly, sensitivity was com-
pared by selecting a second DRS cut-point to matching the
specificity of metabolic syndrome. Statistical significance was
evaluated by p-values obtained using 1000 bootstrap resamplings
in which the entire procedure of selecting DRS cut-points and
comparing sensitivity or specificity were embedded. The two-
sided p-value was determined by the fraction of bootstrapped
samples that resulted in an absolute difference of sensitivity
(specificity) equal to or larger than the observed absolute
difference on the entire data set. Additionally, multiple logistic
regression analysis was done to combine DRS with metabolic
syndrome in a model to determine if metabolic syndrome added
predictive ability to DRS.
To further assess how DRS might impact clinical practice
compared with MetS, Net Reclassification Improvement (NRI)
was employed to compare the classification of subjects by DRS
to the classification by number of MetS risk factors. This
method of analysis was used in both the entire population as
well as a sub-population considered at increased risk based on
recent ADA Clinical Practice Guidelines that define individuals
with; IFG or eHbA1c (i.e. 5.7%–6.4%) to be at increased risk
for diabetes [30]. SSSubjects were categorized by the number of
MetS factors present at baseline: 0–2, 3, or 4–5 factors. To
enable reclassification analysis, two thresholds for the continu-
ous DRS values were selected such that the population
proportions in each of the three DRS categories (Group A, B
and C) matched the proportions in the MetS risk-factor
categories.
NRI was estimated as:
NRI~pr(up D~1)zpr(down jj D~0){
pr(up D~0){pr(down jj D~1)
where D=1 indicates conversion to diabetes, D=0 indicates non-
conversion, up indicates a higher risk classification by DRS than
by MetS, and down indicates a lower classification. The statistical
significance of the NRI was estimated by permutation testing with
10,000 random permutations of the outcome. The p-value was
defined as the fraction of permutations that had greater NRI
values than the observed NRI. A Binomial distribution was also
used to find maximum likelihood estimates and confidence
intervals for conversion to diabetic outcome. chi-square (x2) test
and Wilcoxon test were used to determine differences in factor and
continuous variable, respectively. The statistical significance was
accepted at the p=0.05 level. Differences in mean of biomarker
and MetS factors levels were determined by Analysis of Variance
(ANOVA).
Results
Table 1 describes the baseline clinical characteristics of the
Inter99 population of 4,128 subjects for whom MetS risk factors
also were available in this study. The overall 5-year conversion
rate to T2DM was 4.1% (170 converters). All clinical, DRS
biomarker variables and components of MetS were significantly
different (p-value ,0.05) between converters and non-converters
with the exception of height.
Performance of MetS and DRS in Unselected Population
The accuracy of MetS and DRS, as used in clinical practice, for
assessing risk of developing diabetes is compared in Table 2. Since
in clinical practice, MetS is used as a dichotomous variable, we
used MetS in this way in our analysis. The sensitivity of metabolic
syndrome to predict incident diabetes was 71.4% with a false
positive rate of 27.7%. When DRS was matched on false positive
rate to metabolic syndrome, DRS had a significantly higher
sensitivity (79.9%, p value=0.023). Similarly, when DRS was
matched on sensitivity (71.4%) to metabolic syndrome, DRS has a
significantly lower false positive rate (20.0%, p value=0.011).
When metabolic syndrome was used in combination with DRS,
there was no significant change in the AUC. The ATP-III
thresholds for waist circumference (88 cm for women and 102 cm
for men) were also employed in the analysis (Third Report [33]),
and, while there was an overall decrease in sensitivity and false-
positive rate, DRS was significantly better than MetS by both
criteria (p value ,0.05).
Reclassification of subjects by DRS in the three Met S groups
(i.e. subjects with 0–2, 3, or 4–5 risk factors at baseline) is
summarized in Table 3. Cut-off scores for DRS were established
such that the study cohort was parsed into three groups, each with
the same proportion of subjects as each of the three MetS groups
(DRS Group A, ,4.4; DRS Group B, 4.4–6.8; DRS Group C,
.6.8). The numbers of subjects, population percent, observed rate
of conversion to diabetes during the five year follow-up and the
total number of subjects for each DRS group or MetS group are
shown for each combination of MetS and DRS categories. The
number of subjects reclassified by DRS for each MetS category
also is shown (Reclassified Subtotal).
The overall NRI of 0.146 (p=0.0008) shows that DRS
significantly improved the classification of subjects at risk for
diabetes compared to risk assessment by the number of MetS
factors. Additionally, the reclassification of converters accounts for
most of the NRI (0.147) with a modest reclassification of non-
converters (NRI=20.001), demonstrating an increased specificity
of DRS over MetS without a reduction in sensitivity. The largest
proportion of subjects reclassified by DRS was in the group of
subjects with 3 MetS risk factors. The observed conversion rate to
T2DM for the 746 subjects in the MetS group with 3 risk factors
was 7.4%. DRS reclassified 499 (66.9%) of those subjects; 166
subjects were classified in DRS Group C (i.e. highest risk) with an
observed an observed conversion rate of 18.7% and 333 subjects
were classified into DRS Group A (lowest risk) with an observed
conversion rate of 2.7%.
Among the 470 subjects in the group of 4–5 MetS risk factors,
none of the 122 subjects reclassified by DRS into group A (lowest
risk) converted to diabetes within five years despite having an
elevated risk as assessed by MetS. An ANOVA analysis was
performed for each biomarker quantified for determination of the
DRS and for each MetS risk factor to identify differences in this
cohort with 4–5 MetS factors (Table 4). All biomarkers were
significantly different between the three DRS groups (p,0.001 for
each marker). Among the MetS risk factors, only mean fasting
plasma glucose, waist, and systolic blood pressure were signifi-
cantly different (p-values ,0.001, 0.003 and 0.03 respectively)
between the three DRS groups and increased with increasing
DRS. However, triglycerides and HDL were not significantly
different between the three DRS groups. Further supporting the
accuracy of DRS in assessing risk is the observation that the 93
subjects in the 0–2 MetS group who were reclassified in highest
risk by DRS (Group C) had a higher conversion rate than those
subjects reclassified to low risk by DRS (Group A) in the 4–5 MetS
category (12.9% vs. 0%, respectively).
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Converters Non-converters P-value
Participants 170 3958
Male sex 105 (61.8%) 1945 (49.1%) 0.0015
NFG 37 (21.8%) 2486 (62.8%) 0.0005
IFG 133 (78.2%) 1472 (37.2%) 0.0005
eHbA1c (%) 6.1 (5.8–6.4) 5.8 (5.5–6.0) ,0.0001
IFG or eHbA1c 160 (94.1%) 2909 (73.5%) 0.0005
Family history 55 (32.4%) 637 (16.1%) 0.0005
Age (years) 50.1 (45.0–55.0) 45.1 (40.0–50.2) ,0.0001
Height (cm) 172.0 (166.0–178.0) 172.0 (165.0–179.0) 0.8690
Weight (kg) 84.8 (75.3–98.0) 75.5 (66.0–86.3) ,0.0001
BMI (kg/m
2) 28.6 (26.0–32.3) 25.3 (23.0–28.1) ,0.0001
Waist circumference (cm) 95 (87–107) 85 (76–94) ,0.0001
Hip circumference (cm) 105 (100–111) 100 (94–105) ,0.0001
Systolic blood pressure (mmHg) 140 (130–150) 128 (118–138) ,0.0001
Diastolic blood pressure (mmHg) 86 (80–95) 80 (75–90) ,0.0001
Fasting serum total cholesterol (mmol/L) 5.7 (5.0–6.5) 5.4 (4.7–6.1) 0.0002
Fasting serum HDL cholesterol (mmol/L) 1.2 (1.0–1.5) 1.4 (1.2–1.7) ,0.0001
Fasting serum LDL cholesterol (mmol/L) 3.5 (3.0–4.2) 3.4 (2.8–4.1) 0.0064
Fasting serum triglycerides (mmol/L) 1.6 (1.2–2.2) 1.0 (0.7–1.5) ,0.0001
Fasting serum insulin (pmol/L) 54.5 (35.0–78.0) 32.0 (23.0–48.0) ,0.0001
2-h serum insulin (pmol/L) 302.0 (187.0–448.0) 143.0 (88.0–227.0) ,0.0001
FPG (mmol/L) 6.1 (5.6–6.5) 5.4 (5.1–5.7) ,0.0001
2-h plasma glucose (mmol/L) 8.2 (6.9–9.4) 5.8 (4.9–6.7) ,0.0001
Fasting serum adiponectin (mg/mL) 6.7 (5.4–8.5) 8.4 (6.6–10.8) ,0.0001
Fasting serum CRP (mg/L) 2.2 (1.0–4.0) 0.9 (0.4–2.4) ,0.0001
Fasting serum ferritin (ng/mL) 150.0 (70.3–289.0) 90.7 (41.3–173.0) ,0.0001
Fasting serum IL-2Ra (U/mL) 386.8 (308.4–487.8) 356.3 (285.5–446.7) 0.0026
Data are n (%) or median (interquartile range) for continuous variables. For categorical descriptors, values are counts (percentage of total for that cohort). Differences in
frequency between converters and nonconverters were evaluated with a Monte Carlo estimation of the x
2 statistic (2,000 replicates). Differences in medians of
continuous variables were evaluated with a Wilcoxon test. NFG, normal fasting glucose; IFG, impaired fasting glucose; eHbA1c, elevated hemoglobin HbA1c.
doi:10.1371/journal.pone.0022863.t001
Table 2. Comparison of risk assessment of Metabolic Syndrome and DRS.
AUC Sensitivity (%) False-positive rate (%)
*P-value and
**CI
#PPV
‘NPV
Metabolic Syndrome - 71.4 27.7
Diabetes Risk Score (DRS) 0.836 79.9 27.7 (fixed) 0.023 (0.022–0.157) 10.0% 98.3%
DRS plus Metabolic
Syndrome
0.840 (P=0.128) 79.2 27.7 (fixed) 0.021 (0.018–0.144)
Metabolic Syndrome - 71.4 27.7
DRS 71.4 (fixed) 20.0 0.011 (0.019–0.139) 13.2% 98.5%
DRS plus Metabolic
Syndrome
71.4 (fixed) 17.4 0.009 (0.038–0.0150)
*P for comparison with the row immediately above.
**95% C.I based on observed variance under bootstrap resampling of the differences to MetS.
#=Positive Predictive Value.
‘=Negative Predictive Value.
doi:10.1371/journal.pone.0022863.t002
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# MetS Risk Factors Variable DRS Score Subjects
ABCTotal Reclassified Subtotal
,=4.4 4.4–6.8 .6.8
0–2 Factors No. of Obs. 2457 362 93 2912 455
% of Pop. 59.5% 8.8% 2.3% 70.5% 15.6%
(95% C.I.) (58.0%–61.0%) (7.9%–9.7%) (1.8%–2.8%) (69.1%–71.9%) (14.3%–17.0%)
Conv. Rate 1.1% 3.0% 12.9% 1.7%
(95% C.I.) (0.7%–1.5%) (1.5%–5.4%) (6.8%–21.5%) (1.2%–2.2%)
3 Factors No. of Obs. 333 247 166 746 499
% of Pop. 8.1% 6.0% 4.0% 18.1% 66.9%
(95% C.I.) (7.3%–8.9%) (5.3%–6.8%) (3.4%–4.7%) (16.9%–19.3%) (63.4%–70.3%)
Conv. Rate 2.7% 6.1% 18.7% 7.4%
(95% C.I.) (1.2%–5.1%) (3.4%–9.8%) (13.1%–25.4%) (5.6%–9.5%)
4–5 Factors No. of Obs. 122 137 211 470 259
% of Pop. 3.0% 3.3% 5.1% 11.4% 55.1%
(95% C.I.) (2.5%–3.5%) (2.8%–3.9%) (4.5%–5.8%) (10.4%–12.4%) (50.5%–59.7%)
Conv. Rate 0.0% 14.6% 21.8% 14.0%
(95% C.I.) (0.0%–3.0%) (9.2%–21.6%) (16.4%–28%) (11.0%–17.5%)
Total No. of Obs. 2912 746 470 4128 1213
% of Pop. 70.5% 18.1% 11.4% 100.0% 29.4%
(95% C.I.) (69.1%–71.9%) (16.9%–19.3%) (10.4%–12.4%) (99.9%–100.0%) (28.0%–30.8%)
Conv. Rate 1.2% 6.2% 18.9% 4.1%
(95% C.I.) (0.8%–1.7%) (4.5%–8.1%) (15.5%–22.8%) (3.5%–4.8%)
NRI, (P-value) 0.146 (0.0008)
NRI, Converters 0.147
NRI, Nonconverters 20.001
doi:10.1371/journal.pone.0022863.t003
Table 4. Mean biomarker and risk factor values by DRS for subjects with 4–5 MetS factors.
Variables Mean (SD) P-value
ABC
Fasting serum adiponectin (mg/mL) 7.85 (2.3) 7.05 (2.3) 5.95 (2.0) ,0.001
Fasting serum CRP (mg/L) 1.98 (2.4) 3.14 (3.3.) 5.05 (7.3) ,0.001
Fasting serum ferritin (ng/mL) 132.09 (178.6) 177.54 (166.7) 237.32 (205.4) ,0.001
Fasting serum IL-2Ra (U/mL) 368.65 (156.1) 397.93 (124.3) 450.59 (155.5) ,0.001
Fasting serum insulin (pmol/L) 55.11(26.9) 60.18 (30.1) 70.48 (33.9) ,0.001
HbA1c (%) 5.76 (0.3) 5.89 (0.4) 6.06 (0.5) ,0.001
FPG (mmol/L) 5.54(0.4) 5.81 (0.4) 6.17 (0.4) ,0.001
Fasting serum triglycerides (mmol/L) 2.32 (1.4) 2.4 (1.2) 2.63 (2.0) 0.182
Fasting serum HDL cholesterol (mmol/L) 1.03 (0.2) 1.06 (0.2) 1.06 (0.2) 0.471
Waist circumference (cm) 97 (8) 99 (10) 101 (12) 0.003
Systolic blood pressure (mmHg) 137 (13) 139 (13) 141 (14) 0.029
Diastolic blood pressure (mmHg) 88 (8) 89 (9) 89 (10) 0.452
Mean levels of biomarker and MetS variables within each DRS group (A–C) for all subjects with 4–5 MetS risk factors (n=470). The P-values are calculated by ANOVA.
doi:10.1371/journal.pone.0022863.t004
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Risk for T2DM
The reclassification of subjects with IFG (fasting plasma glucose
between 5.6 and 6.9 mmol/L) and/or eHbA1c (HbA1c between
5.7%–6.4%), a sub-population considered to be at increased risk
for T2DM is summarized in Table 5. Subjects with IFG had a
mean HbA1c of 5.9% with a range of 4.0–7.6%. Cut-off scores for
DRS were determined such that this sub-population was parsed
into three groups, each with the same proportion of subjects as
each of the three MetS groups (DRS Group A, ,4.6; DRS Group
B,4.6–6.9; DRS Group C, .6.9) as done previously in Table 3.
Approximately 74% of subjects (3,069 of 4,128 subjects) in this
study met one or both of these criteria for increased risk. A shift of
subjects to higher risk groups for T2DM was observed based on
risk assessment by MetS or DRS. Patterns of reclassification by
DRS which were similar to those observed in the total population
were observed in this population at increased risk. As observed
with the total population, the largest number of subjects
reclassified by DRS was in the 3 MetS factor group. Subjects in
the MetS group with 4–5 risk factors which were reclassified to
DRS Group A had a conversion rate of 0%, as observed in the
total population. The relative risk between high and low DRS
groups (1.5%–19.7%, relative risk 13.1) was 1.8 fold greater than
the relative risk between the high and low MetS groups (2.1%–
15.0%, relative risk 7.1), consistent with the results observed in the
total population. There is a significant NRI of 0.141 with a p-value
of 0.0032, further highlighting the improved risk stratification of
DRS compared to MetS even in an increased risk population. As
in the total population, the NRI is dominated by the correct
reclassification of converters with a modest reclassification of non-
converters (NRI=0.144 and 20.003, respectively).
Discussion
The objective of this study was to compare the performance of
two risk assessment tools, MetS and DRS, in assessing subjects’ risk
of developing T2DM. The current analysis shows that DRS
provides a superior assessment of diabetes risk compared to MetS
by allowing for more accurate risk stratification of subjects in this
population. Additionally, a model combining MetS with DRS did
not improve the AUC demonstrating that metabolic syndrome
does not provide additional predictive information to DRS.
The absolute risk of diabetes during 5 years in this population
was 4.1% (Table 3), similar to the risk observed in the United
States [31]. Using MetS alone to assess diabetes risk has a
sensitivity of 71.4% and a false positive rate of 27.7% (Table 2).
While presence of MetS is sensitive to identify those subjects at risk
for developing diabetes, it lacks specificity. In this study, about
30% of subjects were classified as having MetS. Among subjects
with MetS the conversion rate was 10.0% while those without
MetS (2 or fewer factors) had a conversion rate of 1.7%, a 5.8 fold
difference in risk, indicating that the presence or absence of MetS
provides a basic level of risk stratification in the total population
Table 5. Reclassification of subjects with impaired fasting glucose and/or elevated HbA1c in three MetS groups by DRS.
# MetS Risk Factors Variable DRS Score Subjects
ABCTotal Reclassified Subtotal
,=4.6 4.6–6.9 .6.9
1–2 Factors No. of Obs. 1556 318 85 1959 403
% of Pop. 50.7% 10.4% 2.8% 63.8% 20.6%
(95% C.I.) (48.9%–52.5%) (9.3%–11.5%) (2.2%–3.4%) (62.1%–65.5%) (18.8%–22.4%)
Conv. Rate 1.3% 3.0% 12.9% 2.1%
(95% C.I.) (0.8%–2.0%) (1.5%–5.7%) (6.6%–22.0%) (1.5%–2.8%)
3 Factors No. of Obs. 286 218 159 663 445
% of Pop. 9.3% 7.0% 5.0% 21.6% 67.1%
(95% C.I.) (8.3%–10.4%) (6.2%–8.1%) (4.4%–6.0%) (20.2%–23.1%) (63.4%–70.7%)
Conv. Rate 3.1% 6.0% 19.5% 8.0%
(95% C.I.) (1.4%–5.9%) (3.2%–10.0%) (13.6%–26.5%) (6.0%–10.3%)
4–5 Factors No. of Obs. 117 127 203 447 244
% of Pop. 4.0% 4.1% 6.6% 14.6% 54.6%
(95% C.I.) (3.2%–4.6%) (3.5%–4.9%) (5.8%–7.6%) (13.3%–15.9%) (49.8%–59.3%)
Conv. Rate 0.0% 15.7% 22.7% 15.0%
(95% C.I.) (0.0%–3.1%) (9.9%–23.3%) (17.1%–29.0%) (11.6%–18.4%)
Total No. of Obs. 1959 663 447 3069 1092
% of Pop. 63.8% 21.6% 14.6% 100.0% 35.6%
(95% C.I.) (62.1%–65.5%) (20.2%–23.1%) (13.3%–15.9%) (99.9%–100.0%) (33.9%–37.3%)
Conv. Rate 1.5% 6.5% 19.7% 5.2%
(95% C.I.) (1.0%–2.1%) (4.7%–8.6%) (16.1%–23.7%) (4.5%–6.1%)
NRI (P-value) 0.1407 (0.0032)
NRI, Converters 0.1438
NRI, Nonconverters 20.0031
doi:10.1371/journal.pone.0022863.t005
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C) had a conversion rate of 18.9% compared to a conversion rate
of 2.2% for subjects in the lower risk DRS groups (Group A
and B).
Counting the number of factors of the MetS present in subjects
provided further stratification of risk for T2DM; subjects with
three risk factors had a conversion rate of 7.4% while those with
4–5 factors had a conversion rate of 14.0%. However, among
those same subjects with 3 MetS factors, DRS was able to further
stratify subjects with a higher degree of accuracy as well as a wider
range of stratification in both the total population and the
population at increased risk (Table 3 and 5). This increased
accuracy of DRS in reclassifying subjects with 3 MetS risk factors
to either lower or higher risk of diabetes provides potential clinical
value by allowing intervention to be focused on those individuals
at highest risk in this group who might be considered to be at
intermediate risk by risk factor counting.
Among those subjects with 4–5 MetS factors, 122 were
reclassified as lowest risk by DRS (Group A, Table 3). In fact,
no subjects in DRS Group A converted to diabetes despite being
classified at highest risk by MetS. As shown in Table 4 all
biomarkers were significantly different between DRS groups
(p,0.001) while only three MetS factors, fasting glucose, waist
and systolic blood pressure showed significant, although small,
differences between these DRS groups. The improved risk
assessment provided by DRS is a function of changes in the seven
markers that are representative of the multiple pathways that are
dysregulated in the development of diabetes.
Overall, DRS provided an enhancement of risk stratification in
comparison with counting the number of MetS risk factors. Within
thegroupofsubjectswith 0–2 MetS riskfactorsthoseinGroupCby
DRS (highest risk) had a higher conversion rate than those subjects
reclassified to Group A (lowest risk) by DRS in the 4–5 MetS
category (12.9% vs. 0%, respectively, Table 3). The stratification of
risk was greater using DRS than the number of MetS factors when
looking at the highest and lowest risk groups. Subjects in DRS
Group C (highest risk conversion rate=18.9%) had 15-fold higher
rate of conversion than did subjects in DRS Group A (lowest risk,
conversion rate=1.2%). By comparison, there was only an 8-fold
difference in conversion rates between the lowest MetS risk group
(i.e. 0–2 factors; 1.7% conversions) and the highest MetS risk group
(i.e. 4–5 factors; 14.0% conversion) (Table 3).
A large proportion of the population was identified in the lowest
risk category by both MetS and DRS (59.5% of total subjects) with
a conversion rate of 1.1%. However, it is important to note that all
subjects classified in the lowest risk category by DRS (Group A)
had a lower risk of conversion to T2DM regardless of the number
of MetS factors in both the total and at risk populations (Tables 3
and 5).
In thisstudy,twoof the threeADA defined risk factorsfor T2DM
(IFG and eHbA1c) (28) were used to identify a sub-population at
increased risk. IFG and eHbA1c were chosen because they can
easily be measured in routine clinical practice. The results show that
DRS more accurately stratified the risk of T2DM in subjects in this
increased risk sub-population (Table 5). This highlights the
improved performance provided by the combination of biomarkers
in DRS compared to MetS factors in accurately identifying those
subjects at increased risk for T2DM even within the population
already identified to be at increased risk.
Both the economic burden and impact on quality of life that
result once an individual becomes diabetic are dramatic [3].
Several long-term prospective clinical trials have shown that
lifestyle intervention can delay and possibly prevent conversion to
T2DM in high-risk individuals [4,5], confirming the need for
easily accessible clinical tests that accurately identify those at
highest risk of conversion. With improved risk stratification
methods, clinicians could focus limited resources and intervention
strategies on those individuals most in need. Although OGTT has
been identified as a strong predictor of diabetes risk, it is rarely
used in clinical practice due to level of difficulty in administering
the test and lack of reproducibility of results [34]. IFG has been
shown to lack specificity in identifying those at highest risk
[6,7,8,9,10]. MetS factors are easily assessable measures for
clinicians but their utility in assessing diabetes risk has been
widely debated [11,13,14,35,36]. As previously noted, Met
Syndrome is relatively sensitive; it has very limited clinical
relevance due to the low specificity. A recent report based on
the evaluation of National Health and Nutrition Examination
Survey (NHANES) 2003–2006 estimated that over one third of the
US adult population had MetS [37] and thus would be identified
as being at risk for developing diabetes. By comparison, DRS is a
simple laboratory test available to clinicians and it may reflect
metabolic disturbances in pathways involved with diabetes better
than MetS factors. DRS provides improved specificity compared
to MetS. This improved specificity was shown here to provide
improved risk stratification and accuracy in assessing risk of
T2DM compared to MetS.
Several limitations are noted. One limitation of this study is that
the DRS algorithm was originally trained on a subset of the Inter
99 population, potentially biasing the results presented here.
However, the training population was a relatively small portion of
the subjects, which were used in the present study and only a
fraction of the available converters and non-converters present
were employed in the training of DRS, thus limiting the potential
bias. Additionally, the performance observed in the sequestered
validation samples was equivalent to the performance in the full
cohort used in the current study as measured by the Area Under
the ROC Curve (0.838 and 0.837, respectively) (24), minimizing
any indication of bias in the results presented here.
Given that there are no guidelines for selecting thresholds for
DRS risk groups, two approaches for the reclassification analysis
were possible. DRS thresholds for assignment to risk groups could
be done by matching risk across categories or by matching
population proportions across categories. We selected the latter
approach. By pre-specifying DRS thresholds based on matching
population proportions potential bias was minimized.
In summary, given the increasing rates of diabetes worldwide,
better tools to identify subjects at highest risk of developing
diabetes are needed. In this study the performance of the multi-
marker DRS model was compared to presence of MetS factors for
assessing risk of incident T2DM. DRS provided improved risk
stratification in all MetS risk factor groups. DRS provides
physicians with a tool to better identify subjects at increased risk
for developing T2DM and allows for interventions to be targeted
to those subjects at highest risk.
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